BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 31466948)

  • 1. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Snider EJ; Freedberg DE; Abrams JA
    Dig Dis Sci; 2016 Aug; 61(8):2217-2225. PubMed ID: 27068172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.
    Lv J; Guo L; Liu JJ; Zhao HP; Zhang J; Wang JH
    World J Gastroenterol; 2019 May; 25(18):2149-2161. PubMed ID: 31143067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
    Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
    Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
    Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus.
    Douville C; Moinova HR; Thota PN; Shaheen NJ; Iyer PG; Canto MI; Wang JS; Dumot JA; Faulx A; Kinzler KW; Papadopoulos N; Vogelstein B; Markowitz SD; Bettegowda C; Willis JE; Chak A
    Gastroenterology; 2021 May; 160(6):2043-2054.e2. PubMed ID: 33493502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosa-Associated Microbiota in Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma Differ Similarly Compared With Healthy Controls.
    Peter S; Pendergraft A; VanDerPol W; Wilcox CM; Kyanam Kabir Baig KR; Morrow C; Izard J; Mannon PJ
    Clin Transl Gastroenterol; 2020 Aug; 11(8):e00199. PubMed ID: 32955191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
    Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
    Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
    United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Lopetuso LR; Severgnini M; Pecere S; Ponziani FR; Boskoski I; Larghi A; Quaranta G; Masucci L; Ianiro G; Camboni T; Gasbarrini A; Costamagna G; Consolandi C; Cammarota G
    PLoS One; 2020; 15(5):e0231789. PubMed ID: 32369505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.